SECURITIES AND EXCHANGE COMMISSION

================================================================================
                             Washington, D.C. 20549

                             ----------------------

                                    FORM 10-Q

(Mark One)

[ X ]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES 
       EXCHANGE ACT OF 1934 for the quarterly period ended December 31, 1997

                                     OR

[   ]  TRANSITION  REPORT  PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
       EXCHANGE  ACT OF 1934 for the  transition  period  from  __________  to
       __________


                        Commission file number: 000-22673



                            SCHICK TECHNOLOGIES, INC.
             (Exact name of registrant as specified in its charter)

                Delaware                                       11-3374812
    (State or other jurisdiction of                          (I.R.S. Employer 
     incorporation or organization)                       Identification Number)
                                                                   



           31-00 47th Avenue                                     11101
       Long Island City, New York                              (Zip Code)
(Address of principal executive offices)

     Registrant's telephone number, including area code: (718) 937-5765



Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days. Yes [ X ] No [ ]

As of February 17, 1998,  9,982,798  shares of common stock,  par value $.01 per
share, were outstanding.

================================================================================


<PAGE>


                            SCHICK TECHNOLOGIES, INC.

                                TABLE OF CONTENTS


PART I.  FINANCIAL INFORMATION:

    Item 1.  Financial Statements:

             Consolidated Balance Sheet as of December 31, 1997 and
             March 31, 1997 ............................................ Page 1

             Consolidated Statement of Operations for the three and 
             nine  months ended December 31, 1997 and 1996 ............. Page 2

             Consolidated Statement of Cash Flows for the nine 
                 months ended December 31, 1997 and 1996................ Page 3

             Notes to Consolidated Financial Statements ................ Page 4

    Item 2.  Management's Discussion and Analysis of Financial 
                 Condition And Results of Operations.................... Page 7

PART II.  OTHER INFORMATION:

    Item 2.  Changes in Securities and Use of  Proceeds................. Page 9

    Item 6.  Exhibits and Reports on Form 8-K........................... Page 10

SIGNATURE............................................................... Page 11

EXHIBIT 11.............................................................. Page 12

EXHIBIT 27.............................................................. Page 16




<PAGE>


PART I.  Financial Information
Item 1.  Financial Statements

                            Schick Technologies, Inc.
                           Consolidated Balance Sheet

<TABLE>
<CAPTION>
                       Assets                           December 31,      March 31, 
                                                            1997            1997
                                                        ------------    ------------
<S>                                                     <C>             <C>
Current assets
  Cash and cash equivalents                             $  8,849,517    $  1,710,429
  Short-term investments                                  16,822,964       2,313,226
  Accounts receivable, net of allowance for doubtful
   accounts of $150,000 and $50,000, respectively          6,920,499       1,927,993
  Inventories                                              8,805,754       2,510,959
  Prepayments and other current assets                       438,025         327,220
                                                        ------------    ------------
         Total current assets                             41,836,759       8,789,827

Equipment, net                                             4,412,326       1,644,528
Investments                                                1,489,973         490,000
Other assets                                                 971,021         135,727
Deferred tax asset                                           434,235            --
                                                        ------------    ------------

         Total assets                                   $ 49,144,314    $ 11,060,082
                                                        ============    ============

       Liabilities and Stockholders' Equity

Current liabilities
  Accounts payable and accrued expenses                 $  4,921,429    $  2,102,293
  Accrued salaries and commissions                         1,524,215         540,061
  Provision for warranty obligations                         519,739         329,426
  Income taxes payable                                       420,374            --
  Deferred revenue                                           329,664         141,017
  Deposits from customers                                    180,830         136,628
  Capital lease obligations, current                            --            22,200
                                                        ------------    ------------
         Total current liabilities                         7,896,251       3,271,625

Notes payable                                                   --         1,512,833
Accrued interest on notes payable                               --           101,654
Capital lease obligations, long-term                            --            86,991
                                                        ------------    ------------
         Total liabilities                                 7,896,251       4,973,103

Commitments                                                     --              --

Stockholders' equity
  Preferred stock ($.01 par value; 2,500,000 shares
   authorized, none issued and outstanding)                     --              --
  Common stock ($.01 par value; 25,000,000 shares
   authorized; 9,982,798 and 7,957,231 shares issued
   and outstanding, respectively)                             99,828          79,572
  Additional paid-in capital                              41,165,798       7,562,766
  Accumulated deficit                                        (17,563)     (1,555,359)
                                                        ------------    ------------
         Total stockholder's equity                       41,248,063       6,086,979

           Total liabilities and stockholders' equity   $ 49,144,314    $ 11,060,082
                                                        ============    ============
</TABLE>


The accompanying notes are an integral part of these consolidated financial
statements.


                                       1
<PAGE>

                            Schick Technologies, Inc.
                      Consolidated Statement of Operations
                                   (unaudited)

<TABLE>
<CAPTION>
                                     Three months ended December 31,  Nine months ended December 31,
                                     -------------------------------  ------------------------------
                                          1997            1996            1997            1996
                                      ------------    ------------    ------------    ------------
<S>                                   <C>             <C>             <C>             <C>         
Revenue, net                          $ 11,911,531    $  4,954,300    $ 26,175,916    $ 10,741,511
Cost of sales                            5,528,685       2,359,777      12,226,464       5,431,095
                                      ------------    ------------    ------------    ------------
           Gross profit                  6,382,846       2,594,523      13,949,452       5,310,416


Operating expenses:
  Selling and marketing                  2,903,561       1,605,038       6,787,070       3,603,418
  General and administrative             1,191,762         559,857       2,923,228       1,290,802
  Research and development               1,288,663         427,236       2,895,812       1,007,722
  Patent litigation settlement                --              --           600,000            --
                                      ------------    ------------    ------------    ------------
     Total operating expenses            5,383,986       2,592,131      13,206,110       5,901,942
                                      ------------    ------------    ------------    ------------

     Income (loss) from operations         998,860           2,392         743,342        (591,526)
                                      ------------    ------------    ------------    ------------


Other income (expense)
   Interest income                         360,488          61,126         858,061         116,174
   Interest expense                        (26,283)        (43,466)        (77,468)       (115,460)
                                      ------------    ------------    ------------    ------------

      Total other income (expense)         334,205          17,660         780,593             714
                                      ------------    ------------    ------------    ------------

    Income (loss) before income tax      1,333,065          20,052       1,523,935        (590,812)
                                      ------------    ------------    ------------    ------------


Provision (benefit) for income
taxes                                      107,721            --           (13,861)           --
                                      ------------    ------------    ------------    ------------

Net income (loss)                     $  1,225,344    $     20,052    $  1,537,796    $   (590,812)
                                      ============    ============    ============    ============

   Earnings (loss) per share          $       0.12    $       --      $       0.17    $      (0.08)
                                      ============    ============    ============    ============
   Earnings (loss) per share
   - assuming dilution                $       0.12    $       --      $       0.16    $      (0.07)
                                      ============    ============    ============    ============
</TABLE>






The accompanying notes are an integral part of these consolidated financial
statements.


                                       2
<PAGE>


                            Schick Technologies, Inc.
                      Consolidated Statement of Cash Flows
                                   (unaudited)

<TABLE>
<CAPTION>
                                                             Nine months ended December 31
                                                             -----------------------------
                                                                 1997            1996
                                                             ------------    ------------
<S>                                                          <C>             <C>
Net cash flows from operating activities:
Net income (loss)                                            $  1,537,796    $   (590,812)
Adjustments to reconcile net loss to net cash       
   (used in) provided by operating activities
   Depreciation and amortization                                  569,530         215,318
   Stock and option grant compensation                             15,141            --
   Accrued interest on investments                               (435,625)           --
   Non-cash interest expense                                         --            98,323
Changes in assets and liabilities:
  Accounts receivable                                          (4,992,506)       (245,561)
  Inventories                                                  (6,127,795)       (528,828)
  Prepayments and other current assets                            (40,728)          7,438
  Other assets                                                    (73,166)        (86,348)
  Deferred income taxes                                          (434,235)           --
  Accounts payable and accrued expenses                         3,993,603       1,533,554
  Income taxes payable                                            420,374            --
  Deferred revenue                                                188,647         107,149
  Deposits from customers                                          44,202          42,636
  Accrued interest on notes payable                              (101,654)         61,500
                                                             ------------    ------------
     Net cash (used in) provided by operating activities       (5,436,416)        614,369
                                                             ------------    ------------

Cash flows from investing activities:
  Investment in capitalized software                              (70,077)           --
  Purchases of available-for-sale investments                        --          (500,000)
  Purchases of held-to-maturity investments                   (15,518,115)     (2,080,130)
  Proceeds from maturities of held-to-maturity investments      1,444,002            --
  Business acquisition                                         (1,450,000)           --
  Purchase of minority interest in Photobit Corporation          (999,973)           --
  Capital expenditures                                         (2,816,455)       (921,661)
                                                             ------------    ------------
                   Net cash used in investing activities      (19,410,618)     (3,501,791)

Cash flows from financing activities:
  Net proceeds from issuance and sale of common stock          33,608,147            --
  Net proceeds from issuance and sale of common stock and
   warrants                                                          --         4,311,800
  Proceeds from issuance of long-term notes                          --         1,000,000
  Repayment of notes payable                                   (1,512,833)           --
  Principal payments on capital lease obligations                (109,192)        (15,648)
                                                             ------------    ------------
               Net cash provided by financing activities       31,986,122       5,296,152

Net increase  in cash and cash equivalents                      7,139,088       2,408,730
Cash and cash equivalents at beginning of period                1,710,429         524,917
                                                             ------------    ------------

Cash and cash equivalents at end of period                   $  8,849,517    $  2,933,647
                                                             ============    ============
</TABLE>


The accompanying notes are an integral part of these consolidated financial
statements.


                                       3
<PAGE>


                            Schick Technologies, Inc.
             Notes to Consolidated Financial Statements (unaudited)
--------------------------------------------------------------------------------

1.   Basis of Presentation

     The consolidated financial statements of Schick Technologies,  Inc. and its
     subsidiaries  (collectively the "Company") have been prepared in accordance
     with  generally  accepted  accounting   principles  for  interim  financial
     information  and the rules of the Securities and Exchange  Commission  (the
     "SEC") for  quarterly  reports on Form 10-Q,  and do not include all of the
     information  and  footnote   disclosures  required  by  generally  accepted
     accounting principles for complete financial  statements.  These statements
     should be read in  conjunction  with the audited  financial  statements and
     notes thereto for the year ended March 31, 1997,  included in the Company's
     Prospectus dated July 1, 1997 forming a part of the company's  Registration
     Statement on Form S-1, as amended ("Form S-1"),  which was initially  filed
     with the SEC on May 13, 1997.

     In the  opinion of  management,  the  accompanying  unaudited  consolidated
     financial  statements  include  all  adjustments   (consisting  of  normal,
     recurring  adjustments)  necessary  for a fair  presentation  of results of
     operations for the interim periods. The results of operations for the three
     and nine months ended December 31, 1997, are not necessarily  indicative of
     the results to be expected for the full year ending March 31, 1998.

     The consolidated financial statements of the Company, at December 31, 1997,
     include the  accounts of the  Company  and its wholly  owned  subsidiaries,
     Schick New York (as hereinafter defined) and Schick X-Ray Corporation.  All
     significant intercompany balances have been eliminated (see Notes 2 and 7).

2.   Restructuring and recapitalization

     In connection with the Company's  initial public offering (the "IPO") under
     the  Securities  Act of  1933,  as  amended,  the  Company  engaged  in the
     following restructuring and recapitalization  transactions.  In April 1997,
     Schick  Technologies,  Inc.  ("Schick  Delaware" or "The  Company") and its
     wholly owned subsidiary,  STI Acquisition  Corporation  ("STI") were formed
     under the General  Corporation Law of the State of Delaware for the purpose
     of forming a holding  company and  changing the state of  incorporation  of
     Schick Technologies, Inc., a New York corporation ("Schick New York" or the
     "Predecessor  Corporation").  Effective  June 4, 1997 (pursuant to a merger
     agreement  among Schick  Delaware,  the  Predecessor  Corporation and STI),
     Schick  Delaware  issued  7,957,231  shares of its common stock for all the
     outstanding  common  stock  of the  Predecessor  Corporation.  STI  and the
     Predecessor  Corporation  merged and the  Predecessor  Corporation  was the
     survivor  of the merger,  and became a  wholly-owned  subsidiary  of Schick
     Delaware.  In connection with the restructuring and merger,  the holders of
     the Predecessor  Corporation's  outstanding  warrants and options converted
     such  warrants  and  options  to  similar  warrants  and  options of Schick
     Delaware  (based on the same  ratio of  exchange,  2.8  shares for 1 share,
     applicable to the common stock  exchange).  Schick  Delaware's  articles of
     incorporation also authorize  2,500,000 shares of preferred stock, $.01 par
     value.

     The 1996 Stock Option Plan of the  Predecessor  Corporation  was amended by
     Schick Delaware and the shares available for issuance  pursuant to the Plan
     were adjusted to 470,000.  Schick Delaware also  implemented its 1997 Stock
     Option Plan for  Non-Employee  Directors  ("the  Directors  Plan")  whereby
     nonqualified  options  to  purchase  up to 35,000  shares of the  Company's
     common stock may be granted to non-employee directors.  Each option granted
     under the Directors Plan becomes exercisable on the second anniversary date
     of its grant and must have an exercise price equal to the fair market value
     of the Company's common stock on the date of grant.

     All common  shares,  stock  options,  warrants  and  related per share data
     reflected in the accompanying  financial statements and notes thereto, have
     been  presented  as if the  recapitalization  had  been  effective  for all
     periods presented.

     References herein to the operations and historical financial information of
     the  "Company"  prior  to  the  date  of  the  restructuring  refer  to the
     operations  and  historical   financial   information  of  the  Predecessor
     Corporation.


                                       4
<PAGE>


                            Schick Technologies, Inc.
             Notes to Consolidated Financial Statements (unaudited)
--------------------------------------------------------------------------------

3.   Inventories

     Inventories  at December  31, 1997 and March 31, 1997 are  comprised of the
     following:
                                             December 31,         March 31,
                                                 1997                1997
                                              ----------          ----------
Raw materials ..........................      $6,537,056          $1,671,010
Work-in-process ........................         752,889             421,863
Finished goods .........................       1,515,809             418,086
                                              ----------          ----------

    Total inventories ..................      $8,805,754          $2,510,959
                                              ==========          ==========


4.   Initial Public Offering

     In July 1997, the Company  completed the IPO,  selling  2,012,500 shares of
     common stock at a price of $18.50 per share providing gross proceeds to the
     Company of $37,231,250 and net proceeds,  after underwriting  discounts and
     commissions  and estimated  offering  expenses  payable by the Company,  of
     approximately $35,508,000.

     In July 1997,  upon the  declaration of the  effectiveness  of the Form S-1
     filed in connection  with the IPO, the Company  repaid,  as required by the
     note  agreement,  a  secured  note  payable  in  the  principal  amount  of
     $1,512,833 and accrued interest thereon in the amount of $144,296.

5.   Patent Litigation Settlement

     In July 1997,  the Company , in connection  with the  settlement of certain
     pending patent  litigation  involving a United States patent  directed to a
     display  for  digital   dental   radiographs,   was  granted  a  worldwide,
     non-exclusive  fully paid license covering such patent in consideration for
     a payment by the Company of $600,000.  The Company expensed the license fee
     in the quarter ended June 30, 1997.

6.   Keystone Acquisition

     On September 24, 1997, the Company's wholly owned subsidiary,  Schick X-Ray
     Corporation  ("Schick  X-Ray"),  a Delaware  corporation,  acquired certain
     assets of Keystone Dental X-Ray Inc. ("Keystone"),  a manufacturer of x-ray
     equipment for the medical and dental  radiology  field,  for  $1,450,000 in
     cash.  Schick X-Ray was formed on September 24, 1997,  for the sole purpose
     of acquiring  the assets of  Keystone.  Schick  X-Ray  acquired  inventory,
     manufacturing equipment, tooling and intellectual property. The acquisition
     has been  accounted  for using the  purchase  method,  and Schick X-Ray has
     recorded  goodwill  in the  amount  of  approximately  $750,000,  which  is
     included in other  assets and will be amortized  on a  straight-line  basis
     over 10 years.

7.   Investment in Photobit Corporation

     On September 30, 1997, the Company purchased a minority interest of 5%, for
     approximately   $1,000,000,   in  Photobit  Corporation,   a  developer  of
     complementary  metal-oxide  semiconductor  ("CMOS"),   active-pixel  sensor
     ("APS") imaging  technology.  The Company is the exclusive  licensee of the
     APS technology for medical applications and plans to utilize the technology
     in its bone-mineral density device.

8.   Net Income (Loss) Per Common Share

     Effective  December 31, 1997,  the Company  adopted  statement of Financial
     Accounting  Standards  No.  128,  "Earnings  per Share"  ("FAS  128") which
     requires presentation of basic earnings per share ("Basic EPS" or "earnings
     per share") and diluted  earnings per share ("Diluted EPS" or "earnings per
     share - assuming  dilution").  Basic EPS is  computed  by  dividing  income
     available to common stockholders by the  weighted-average  number of common
     shares  outstanding  during the  period.  Diluted  EPS gives


                                       5
<PAGE>

     effect to all  dilutive  potential  common  shares  outstanding  during the
     period. The computation of Diluted EPS does not assume conversion, exercise
     or contingent exercise of securities that would have an antidilutive effect
     on earnings.  The adoption of FAS 128 did not have a significant  effect on
     earnings per share for the three and nine months ending December 31, 1996.

     The  computation  of earnings  per share and  earnings per share - assuming
     dilution for the three and nine month periods  ended  December 31, 1997 and
     1996 are as follows:

<TABLE>
<CAPTION>
                                                  Three months ended           Nine months ended 
                                                      December 31,                December 31,
                                               -------------------------   -------------------------
                                                  1997          1996          1997          1996
                                               -----------   -----------   -----------   -----------
<S>                                            <C>           <C>           <C>           <C>         
     Income (loss) available common
        stockholders                           $ 1,225,344   $    20,052   $ 1,537,796   $  (590,812)
     Interest on convertible notes                    --            --            --          23,366
     Income (loss) for earnings per share -
        assuming dilution                      $ 1,225,344   $    20,052   $ 1,537,796   $  (567,446)
                                               ===========   ===========   ===========   ===========
     Weighted average shares outstanding for
        earnings (loss) per share                9,981,154     7,920,484     9,307,598     7,543,199
     Dilutive effect of stock options and
        warrants                                   432,477       161,297       518,861       579,612
                                               -----------   -----------   -----------   -----------
     Weighted average shares outstanding for
        earnings (loss) per share - assuming    10,413,631     8,081,781     9,826,459     8,122,811
        dilution
     
     Earnings per share                        $      0.12   $      --     $      0.17   $     (0.08)
                                               ===========   ===========   ===========   ===========
     Earnings per share - assuming dilution    $      0.12   $      --     $      0.16   $     (0.07)
                                               ===========   ===========   ===========   ===========
</TABLE>



                                       6
<PAGE>

Item 2.  Management's Discussion and Analysis of Financial
               Condition and Results of Operations

This Quarterly report on Form 10-Q contains  forward-looking  statements  within
the  meaning of Section  27A of the  Securities  Act of 1933,  as  amended,  and
Section 21E of the Securities Exchange Act of 1934, as amended.  Actual results,
events and  circumstances  could differ  materially from those set forth in such
statements due to various  factors.  Such factors include the changing  economic
and competitive conditions in the medical and dental digital radiography market,
regulatory  approvals,  technological  developments,  protection  of  technology
utilized by the Company,  patent infringement  claims and other litigation,  and
further risks and uncertainties, including those detailed in the Company's other
filings with the Securities and Exchange Commission.

General

The Company  designs,  develops and  manufactures  digital  imaging  systems and
devices  for the dental and  medical  markets.  In the field of  dentistry,  the
Company has developed,  and currently  manufactures  and markets,  an intra-oral
digital  radiography  system.  The  Company has also  developed  a bone  mineral
density measurement device to assist in the diagnosis of osteoporosis, which was
introduced  in December of 1997,  upon receipt of FDA  marketing  clearance.  In
addition, the Company is developing large-area  radiographic imaging devices for
digital mammography.

Results of Operations

Net revenue for the three months ended December 31, 1997, increased $6.9 million
(140%) to $11.9 million from $5.0 million for the comparable period of 1996. Net
revenue for the nine months ended  December 31, 1997,  increased  $15.5  million
(144%) to $26.2  million from $10.7 million for the  comparable  period of 1996.
The increase was attributable  principally to an increase in the number of CDRTM
products sold. Also contributing to the increase in sales for the three and nine
months ended December 31, 1997, was the introduction of the Company's AccudexaTM
bone  density  measurement  device  in  December  of 1997.  The  number of CDRTM
products sold was positively affected by the Company's increased expenditures on
sales and  marketing,  personnel  recruiting,  promotional  activities,  and the
increased use of domestic dental distributors.

Cost of sales for the three months  ended  December  31,  1997,  increased  $3.2
million  (134%) to $5.5 million  (46.4% of net revenue) from $2.3 million (47.6%
of net revenue) for the  comparable  period of 1996.  Cost of sales for the nine
months ended  December 31, 1997,  increased $6.8 million (125%) to $12.2 million
(46.7%  of net  revenue)  from  $5.4  million  (50.6%  of net  revenue)  for the
comparable  period of 1996. The increase was due to the increase in sales of the
Company's  products.  The decrease as a percentage  of net revenue was primarily
due  to  increased  manufacturing  efficiencies,  increased  production  yields,
economies of scale  generated by an increase in the number of products sold, and
decreased warranty costs.

Selling and marketing  expenses for the three months  ending  December 31, 1997,
increased $1.3 million  (80.9%) to $2.9 million (24.4% of net revenue) from $1.6
million  (32.4% of net revenue) for the comparable  period of 1996.  Selling and
marketing expenses for the nine months ending December 31, 1997,  increased $3.2
million (88%) to $6.8 million (25.9% of net revenue) from $3.6 million (33.5% of
net  revenue)  for the  comparable  period of 1996.  The increase in dollars was
attributable  principally  to the hiring and training of new  salespeople as the
Company continued to increase the size of its national sales force. In addition,
the Company significantly increased its promotional activities to create greater
market awareness, and developed market strategies for new products.

General and  administrative  expenses for the three  months  ended  December 31,
1997, increased $632 thousand (112.9%) to $1.2 million (10% of net revenue) from
$560 thousand (11.3% of net revenue) for the comparable period of 1996.  General
and  administrative  expenses  for the nine  months  ended  December  31,  1997,
increased $1.6 million (126.5%) to $2.9 million (11.2% of net revenue) from $1.3
million (12% of net revenue) for the comparable period of 1996. The increase was
primarily attributable to the hiring of administrative  personnel and legal fees
associated with patent infringement litigation.

Research and development  expenses for the three months ended December 31, 1997,
increased $861 thousand  (202%) to $1.3 million (10.8% of net revenue) from $427
thousand (8.6% of net revenue) for the comparable  period of 1996.  Research and
development expenses for the nine months ended December 31, 1997,


                                       7
<PAGE>

increased  $1.9 million  (187%) to $2.9 million (11.1% of net revenue) from $1.0
million (9.4% of net revenue) for the  comparable  period of 1996.  The increase
was  attributable  to the expenses  associated  with the  development  of a bone
mineral density measurement device,  enhancements to the Company's products, and
initial development of a mammography system.

In July 1997, the Company,  in connection with the settlement of certain pending
patent  litigation  involving a United States  patent  directed to a display for
digital dental  radiographs,  was granted a worldwide,  non-exclusive fully paid
license  covering such patent in  consideration  for a payment by the Company of
$600 thousand.

Interest  income  increased to $360 thousand in the three months ended  December
31, 1997 from $61 thousand in the  comparable  period of 1996.  Interest  income
increased to $850 thousand in the nine months ended  December 31, 1997 from $116
thousand in the comparable  period of 1996.  These increases are attributable to
higher cash balances and investments in  interest-bearing  securities which were
purchased  with the proceeds of the July 1, 1997 Initial  Public  Offering  (the
"IPO").  Interest expense  decreased to $26 thousand for the three-month  period
ended  December  31, 1997 from $43  thousand in the  comparable  period of 1996.
Interest  expense  decreased  to $77 thousand  for the  nine-month  period ended
December 31, 1997 from $115 thousand in the comparable period of 1996.  Interest
expense was  attributable  principally to the Merck Loan,  which was repaid from
the proceeds of the IPO.

Liquidity and Capital Resources

At December 31, 1997, the Company had $8.8 million in cash and cash equivalents,
$16.8 million in  short-term  investments  and $33.9 million in working  capital
compared  to  $1.7  million  in cash  and  cash  equivalents,  $2.3  million  in
short-term  investments  and $5.5 million in working  capital at March 31, 1997.
The increase in working  capital for the nine months ended December 31, 1997, is
primarily  attributable to the net proceeds from the issuance and sale of common
stock in connection with the Company's IPO (see below).

On July 7, 1997, the Company sold 1,750,000  shares of common stock in an IPO at
a price of $18.50  per  share,  resulting  in net  proceeds  to the  Company  of
approximately $28.9 million after deducting expenses.  In addition,  on July 10,
1997, the Company received approximately $4.5 million, net of expenses, upon the
exercise of the underwriters'  over-allotment  option to purchase 262,500 shares
of common  stock.  A portion of the proceeds from the IPO was used to retire the
debt due Merck & Co. in the  principal  amount of $1.5  million and  interest of
$144  thousand  (the "Merck  Loan").  Additional  proceeds were used to purchase
assets in Keystone  Dental X-Ray Inc.  ("Keystone")  and a minority  interest in
Photobit Corporation ("Photobit") as described below. The remaining proceeds are
expected  to be used  (i) to  expand  the  Company's  research  and  development
capabilities,  (ii) to expand its sales and marketing effort,  (iii) for working
capital  and  general  corporate  purposes,   and  (iv)  for  expansion  of  its
facilities.  Pending  such  uses,  the  Company  invests  the  net  proceeds  in
investment-grade,  interest-bearing  securities.  From time to time, the Company
may evaluate  potential  acquisitions  of assets,  businesses and product lines,
which would complement or enhance the business of the Company.  Depending on the
cash  requirements  of any  such  acquisition,  the  Company  may  finance  such
acquisition, in whole or in part, with a portion of the net proceeds of the IPO.

On September  24, 1997,  the  Company's  wholly owned  subsidiary,  Schick X-Ray
Corporation,   acquired  certain  assets  of  Keystone  Dental  X-Ray,  Inc.,  a
manufacturer of x-ray equipment for the medical and dental  radiology field, for
$1.5 million in cash. Schick X-Ray acquired inventory,  manufacturing equipment,
tooling and intellectual  property. The acquisition has been accounted for using
the purchase method.

On  September  30,  1997,  the Company  purchased  a minority  interest of 5% in
Photobit   Corporation,   a  developer  of  sensor   imaging   technology,   for
approximately  $1.0 million.  The Company is the exclusive licensee of a certain
technology for medical  applications  and plans to utilize the technology in its
bone mineral density measurement device.



                                       8
<PAGE>


PART II  OTHER INFORMATION

Item 2.  Changes in Securities and Use of Proceeds

(c) On October 6, 1997, Cintel Investments exercised Warrants to purchase 11,200
shares of the Company's  Common Stock for an exercise  price of $8.93 per share,
or $100,016.00 in the aggregate.

     Subsequently, on November 21, 1997, Robert Berger CPA Keogh Plan elected to
make a cashless  surrender of Warrants  exercisable  to purchase 2,800 shares of
common  stock for an  exercise  price of $8.93 per share and in return  received
1,867 shares of the Company's  Common  Stock.  Such  issuances  were pursuant to
Section 4(2) of the Securities Act of 1933, as amended.

(d) On July 7, 1997, the Company's  initial public offering (the  "Offering") of
1,750,000  shares of its common  stock,  $.01 par value per share  (the  "Common
Stock") closed. The Company's  registration  statement on Form S-1 (Registration
No. 333-33731) was declared effective by the Securities and Exchange  Commission
on  June  30,  1997.  As  part  of the  Offering,  the  Company  granted  to the
Underwriters  over-allotment  options to purchase up to 262,500 shares of Common
Stock  ("the  "Underwriters'  Option").  On  July  10,  1997,  the  underwriters
exercised the  Underwriters'  Option  purchasing  262,500 shares of Common Stock
from the Company.  The aggregate  offering  price of 2,012,500  shares of Common
Stock  registered  for the  account  of the  Company  pursuant  to the  Offering
(inclusive of the Underwriters' Option) was $37,231,250.

     The managing underwriter for the Offering was Lehman Brothers.  The co-lead
underwriters were J.P. Morgan & Co. and Pacific Growth Equities, Inc.

     The aggregate  offering price of the 2,012,500  shares of Common Stock sold
in the Offering to the public was  $37,231,250  (inclusive of the  Underwriters'
Option),  with  proceeds to the Company  (after  deduction  of the  underwriting
discount and  commissions in the amount of  $2,606,188)  of $34,625,062  (before
deducting offering expenses payable by the Company).

     During the period of July 1, 1997 through  December 31, 1997, the aggregate
expenses   incurred  by  the  Company  in  connection   with  the  issuance  and
distribution  of the shares of Common  Stock  offered and sold in the  Offering,
including  accounting,   legal,   printing  and  other  expenses,   amounted  to
$1,116,932.

     As the Company's legal counsel in connection with the Offering,  Kelly Drye
& Warren LLP received  legal  expenses paid by the Company.  Mark Bane,  Esq., a
partner of Kelly Drye & Warren LLP, is a director of the Company. Other than the
payment by the Company of legal expenses to Kelly Drye & Warren LLP, none of the
expenses paid by the Company in connection  with the Offering or the exercise of

                                       9
<PAGE>

the  Underwriters'  Option were paid,  directly  or  indirectly,  to  directors,
officers,  controlling  stockholders  (e.g.,  persons  owning 10% or more of any
class of the Company's stock) of the Company, or affiliates.

     The aggregate net proceeds received by the Company from the Offering and as
a  result  of  the  exercise  of  the  Underwriters'   Option,  after  deducting
underwriting and commissions and expenses were $33,508,731. During the period of
July 1, 1997 through  December 31, 1997,  such net proceeds have been applied as
follows: (i) $597,517 for leasehold improvements;  (ii) $1,555,725 for property,
plant,  and equipment;  (iii)  $1,450,000 to purchase certain assets of Keystone
Dental X-Ray Corp.; (iv) $1,000,000 to purchase a 5% interest in Photobit, Inc.;
(v) $1,512,833 to pay the notes payable and the interest thereon to Merck & Co.,
Inc.;  (vi)  $15,518,115 to short term  investments;  (vii)  $6,386,897 to money
market  investments;  and (viii) the remaining  $5,487,644  was used for working
capital purposes. None of the net proceeds were paid, directly or indirectly, to
directors, officers, controlling stockholders, or affiliates of the Company.


Item 6.  Exhibits and Reports on Form 8-K.

(a)      Exhibits

         (11)     Statement re: Computation of Per Share Earnings

         (27)     Financial Data Schedule

(b)      Reports on Form 8-K:

          A report on Form 8-K was filed on  October  9, 1997  reporting  (under
          Item 2) the  purchase of certain  assets by Schick  X-Ray  Corporation
          from Keystone Dental X-Ray, Inc.







                                       10
<PAGE>


                            SCHICK TECHNOLOGIES, INC.
                                    SIGNATURE


Pursuant  to the  requirement  of the  Securities  Exchange  Act  of  1934,  the
registrant  has duly  caused  this  Report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


                                          SCHICK TECHNOLOGIES, INC.



Date:   February 17, 1998                 By: /S/  David B. Schick
                                              -------------------------
                                                   David B. Schick
                                                   President and
                                                   Chief Executive Officer



                                          By: /S/  David B. Spector
                                              -------------------------
                                                   David B. Spector
                                                   Chief Financial Officer and
                                                   Treasurer
                                                   (Principal Financial Officer)



                                       11